Key result
Three-dimensional echocardiography and global longitudinal strain provide superior sensitivity over 2D LVEF for early detection of cancer therapy-related cardiac dysfunction.
Why the study?
While left ventricular ejection fraction is the most widely used index to quantify cardiac function in cardio-oncology, multiple other echocardiographic indices remain under investigation to prove their prognostic value for adverse cardiac events during cancer therapy.
Does comprehensive echocardiographic monitoring incorporating 3D LVEF and global longitudinal strain improve early detection and prognosis of cancer therapy-related cardiac dysfunction compared to standard 2D LVEF in patients undergoing antitumor treatment?
Does comprehensive echocardiographic monitoring incorporating 3D LVEF and global longitudinal strain improve early detection and prognosis of cancer therapy-related cardiac dysfunction compared to standard 2D LVEF in patients undergoing antitumor treatment?
Answers are grounded in this paper and cite their sources.
This literature review highlights the critical role of 3D echocardiography and global longitudinal strain (GLS) alongside baseline HFA-ICOS risk stratification for the early detection and monitoring of cancer therapy-related cardiac dysfunction, aligning with the 2022 ESC Cardio-Oncology guidelines.
The paper presents a summary of the literature that includes the results of the research on the echocardiographic parameters for the early detection and monitoring of the cardiac toxicity of the antitumor treatment. While the left ventricular ejection fraction is currently the most widely used index to quantify cardiac function in cardio-oncology, there are a number of indices under investigation to prove their prognostic value in the occurrence of adverse cardiac events during cancer therapy. Such indices derived from the Doppler method, speckle tracking parameters, strain rate as well as parameters derived from three-dimensional echocardiography, which can provide additional sensitivity and substantial prognostic value for future cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Daniela Bursacovschi (2023) conducted a review in Cancer patients undergoing potentially cardiotoxic antitumor therapy. Echocardiographic monitoring (3D LVEF, global longitudinal strain, Doppler parameters) vs. Conventional 2D LVEF assessment was evaluated on Early detection and prognostic evaluation of cancer therapy-related cardiac dysfunction (CTRCD). Three-dimensional echocardiography and global longitudinal strain provide superior sensitivity over 2D LVEF for early detection of cancer therapy-related cardiac dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: